EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Intravenous lidocaine does not provide additional pain reduction beyond placebo in probable nociplastic chronic low back pain: a randomized controlled equivalence trial

Subrata Pahari, Sandipan Hazra, Partha Pratim Das

Pain Medicine · 2026-11-01 · 27 (11) · 1200-1209

DOI: 10.1093/pm/pnag093 ↗
AbstractBibliografische Angaben

Abstract

Abstract Importance Evidence supporting repeated intravenous lidocaine infusions for probable nociplastic chronic non-specific low back pain remains limited despite its use as a centrally acting analgesic in several chronic pain conditions. Objective To evaluate whether repeated intravenous lidocaine infusions provide clinically meaningful benefit beyond placebo for pain reduction in probable nociplastic chronic non-specific low back pain. Setting Department of Physical Medicine and Rehabilitation, NRS Medical College and Hospital. Participants Eighty-four adults with chronic non-specific low back pain and probable nociplastic pain features. Interventions Participants were randomized equally to receive either intravenous lidocaine (1 mg/kg bolus followed by 4 mg/kg infusion weekly for 4 weeks) or placebo saline infusion. All participants received background multimodal pain management consisting of amitriptyline and aerobic exercise. Main Outcomes The primary endpoint was the between-group difference in Visual Analogue Scale (VAS) pain intensity at 3 months. Therapeutic equivalence was assessed using a prespecified equivalence margin of ±1.5 VAS units and the two one-sided tests (TOST) framework. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index [PSQI]) and functional disability (Quebec Back Pain Disability Scale [QBPDS]). Results At 3 months, the between-group difference in VAS was 0.24 (90% CI, −0.33 to 0.81), entirely within the predefined equivalence bounds, confirming therapeutic equivalence (TOST P < .001). Both groups improved significantly over time without a significant group × time interaction. Improvement in sleep quality was greater in the lidocaine group (mean difference in change score, 1.81; 95% CI, 0.49-3.14; P = .027). Functional improvement numerically favored lidocaine, although continuous disability outcomes were not significantly different. Adverse events were more common in the lidocaine group but were mild, transient, and self-limiting. Conclusion Repeated intravenous lidocaine infusions did not provide additional analgesic benefit over saline infusions administered alongside multimodal pain management in patients with probable nociplastic chronic non-specific low back pain. Relevance These findings support prioritizing evidence-based multimodal pain management, including exercise and centrally acting pharmacological therapy, over routine adjunctive intravenous lidocaine for probable nociplastic chronic non-specific low back pain. Clinical trial registration number CTRI/2024/07/070888. Clinical trials Registry-India (CTRI) https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTA4ODk1&Enc=&userName=.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →